3rain tumors represent the most common solid tumor in children. Fractionated radiation therapy has been an important treatment modality in the mUlti-disciplinary management of these tumors. Stereotactic radiosurgery is the precise delivery of a single fraction of radiation and has been an important treatment option for adult brain tumor patients. Although the use of stereotactic radiosurgery in pediatric brain tumors is much less frequent, it represents an important alternative for patients with recurrent, surgically inaccessible or radioresponsive tumors. This article will review the results and logistical issues of this modality in the management of pediatric brain tumors.
Introduction
Brain tumors represent the most common solid tumor in children and account for approximately 20% of all childhood malignancies. Radiation therapy has been an important treatment modality in the multi-disciplinary management of these tumors.
Stereotactic radiosurgery (SRS) is a conformal radiation technique that has been used frequently in adult patients to treat a variety of intracranial tumors, functional disorders, and vascular malformations. Unlike conventional radiotherapy, SRS enables the neurosurgeon and radiation oncologist to deliver a high, single dose of radiation to a precisely defined radiographic target to stop tumor growth while minimizing the dose to the surrounding normal tissue. The technique has been criticized, though, over concerns' about single fraction treatment and the potential for normal tissue damage. Given these concerns, the use of stereotactic radiotherapy or fractionated SRS has been advocated for some tumors based on histology, size and location. This approach combines the radiobiologic advantages of fractionation with the precision of radiosurgery.
Based on the extensive literature regarding the use of SRS in adult patients, this modality has been used for some pediatric brain tumors. The use of SRS for such tumors is particularly appealing for patients with recurrent, surgicaIly inaccessible, or radioresponsive tumors. This article will review the results of SRS in pediatric patients with brain tumors.
iospinal irradiation (CSI) with posterior fossa boost and chemotherapy. Studies have demonstrated a clear doseresponse relationship using fractionated treatment approaches (1). To minimize the potential toxicities from treatment of the entire posterior fossa, the use of 3D conformal radiotherapy and failure patterns have been evaluated (2) (3) (4) . Stereotactic radiosurgery would appear to be a potential option to focally escalate radiation dose. However, the number of reports using SRS in managing newly diagnosed and recurrent medulloblastoma is sparse (5) (6) (7) .
Patrice et al. reported on 14 children (II with recurrent and 3 with newly diagnosed medulloblastoma) who underwent SRS (5) . The 3 children with primary tumors underwent SRS boost for residual disease that remained after fractionated radiotherapy. They were alive without recurrence after a median follow-up of 27 months. The II children with recurrent disease survived for 10 months. Hodgson et al. updated these results and reported on 16 children with medulloblastoma (6) . The median progression free survival was II months with a 3-year actuarial local control of 57%. Patients were more likely to relapse outside the SRS area of volume.
Another series from Woo and colleagues evaluated the use of SRS as a boost in 4 newly diagnosed patients (2 children) (7) . All patients had SRS boost after CSI and posterior fossa boost. The SRS boost doses ranged from 4.5 to 10 Gy and were administered I week to 4 months after completing CSI. All 4 patients were without recurrence at follow-up (range, 8 to 35 months).
Based on these small series, SRS may have a role in managing residual or recurrent disease. Because current medulloblastoma trials are not incorporating SRS, its role in the management of these tumors may remain unknown for some time.
Ependymomas
Ependymomas represent 5% to 10% of pediatric brain tumors and occur most frequently in the posterior fossa. The extent of surgical resection has been shown to influence recurrence rates and survival (8, 9) . Following gross total resection, local control rates of 50% to 70% can be achieved using doses of 54 to . Recently, 3D conformal radiation therapy with smaller margins has been used (13). Because the failure pattern is predominantly local, SRS represents an attractive treatment option to improve control for newly diagnosed and recurrent tumors.
Aggarwal reported on the St. Jude's experience of 5 children with localized intracranial ependymoma who received SRS boost (14) . AIlS patients received wide field local radiation using a dose of 50.4 to 55.8 Gy at 1.5 to 1.8 Gy per fraction. Stereotactic radiosurgery was used as a boost to residual enhancing tumor within 30 days of radiation therapy in 4
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patients and at 6 months in the fifth patient after 50.4 to 55.8 Gy. The treatment was well tolerated with limited toxicity. Three children had complete response.
Stafford reported the Mayo Clinic's experience of 12 adult and pediatric patients with recurrent ependymoma (I5). Eleven of the 12 patients had undergone previous surgery and external beam radiation therapy. The median age at SRS was 29 years (range, 5 to 56 years). Using a median dose of 18 Gy, local control was achieved in 14 of the 17 tumors with an estimated 3-year local control of 68%. One patient experienced radiation necrosis.
Results from the Joint Center for Radiation Therapy, which consisted of 28 pediatric patients with recurrent or residual disease, showed a median progression free survival of 8.5 months (6) . The 3-year actuarial local control was 29%. The predominant failure pattern was local for patients with residual disease postoperatively.
These reports suggest that SRS may be an effective treatment for patients with recurrent or residual disease. Further studies are needed to determine its role in the management of these patients.
Low-Grade Astrocytomas
Low-grade astrocytomas, including fibrillary and pilocytic tumors, represent a diverse group of common pediatric brain tumors that can have an indolent course. Treatment options depend on the location and extent of disease. For patients who undergo gross total resection or subtotal resection, the value of immediate postoperative radiation is controversial. In general, radiation therapy is used for those patients who have recurrent or unresectable disease. For smaller tumors, brachytherapy has been used by some European centers (16, 17) . The pediatric experience of SRS is limited; it has been used primarily for patients with residual, recurrent, or surgically inaccessible lesions.
Hadjipanayis reported the University of Pittsburgh's experience of 37 patients with recurrent or unresectable pilocytic astrocytomas (I 8) . This paper updated the previous report from Somaza and included adult patients who underwent SRS as part of the multi modal treatment for pilocytic astrocytomas (19) . Twenty-five of the 37 patients (68%) were 18 years old or younger. Tumor volumes varied from 0.42 to 25 cc. The median prescription dose was 15 Gy. Eighteen of the 37 patients experienced a complete response or reduced tumor volume. Two patients experienced a temporary worsening of their neurologic condition after SRS. tumor volume was 2.2 cc, and the prescription dose ranged from 9 to 20 Gy (median, lOGy). With a median radiographic follow-up of 4.7 years, 85% of the patients achieved moderate tumor reduction. Tumor control was achieved in 18 of the 19 patients. Increased contrast enhancement and edema were noted in 25% of patients generally within 7 months of treatment.
Barcia reported on 16 deeply seated inoperable low-grade gliomas (21) . Six were previously treated with conventional radiotherapy. A mean dose of 21.7 Gy was used. Fifty percent of tumors had a complete response to SRS, and 31% stabilized or decreased in size. The 3 patients with brain stem lesions did not respond to treatment and died as a result of their disease.
Based on these results, the use of SRS in low grade gliomas may be warranted for selected patients. Its use is probably best suited for patients with inoperable or residual tumor after surgery. Future studies are needed to corroborate the published results.
High-grade Gliomas
High-grade gliomas account for approximately 15% of primary pediatric CNS malignancies. Although the management of these tumors has improved, the overall results remain dismal. Because 80% to 90% of failures will occur within the 2 em of the original tumor, the radiation dose is commonly escalated. Although focal radiation techniques such as SRS can be used to escalate the radiation dose, the pediatric literature of SRS for malignant gliomas is very limited.
Glioblastoma multi forme (GBM) and anaplastic astrocytomas represented 20% of the pediatric tumors treated with SRS at the Joint Center for Radiation Therapy from 1987 through 1997 (6) . The progression free survival following SRS was 12 months. The 3-year actuarial local control was 50%. Four of the 20 patients enrolled in this study were alive and free of progression at 50, 62, 66, and 119 months, respectively. The University of California at San Francisco's experience of II patients with high-grade gliomas, which included ependymomas and medulloblastomas, was poor (22) . Local control was achieved in 5 of the 14 high-grade gliomas.
The Children's Cancer Study Group (CCG) started a pilot study (CCG 9951) of SRS for recurrent brain tumor patients in March 1995. Patients were eligible if they were 21 years of age and younger and had a recurrent brain tumor that was 3.5 em or less in diameter. The goal of the study was to assess the feasibility of using SRS to treat such tumors and its complications. Unfortunately, this study was closed prematurely secondary to poor accrual. The Pediatric Oncology Group (POG) also had to close a phase II trial (POG 9373) of SRS for recurrent or metastatic brain tumors. This study 143 accrued only 7 patients over a period of 4 years. Currently, there are no prospective Children's Oncology Group trials evaluating the use of SRS.
Recently, the Radiation Therapy Oncology Group (RTOG) reported the results of a phase III trial for adult patients with GBM (23) . This trial randomized patients into one of two groups: SRS followed by RT and BCNU or RT and BCNU. The results showed that the SRS arm did not improve survival. Based on this study, the use of SRS in the initial management of GBM is not recommended, although it remains a reasonable option at recurrence.
Craniopharyngiomas
Craniopharyngiomas are the most common benign pediatric brain tumor. The optimal management remains controversial given the many treatment options that are available. Fractionated radiation therapy and brachytherapy have been important treatment options for patients with this type of tumor and have been used for partially resected, recurrent, and newly diagnosed tumors. 111e use of SRS is appealing because these are well circumscribed tumors but also potentially concerning because these tumors develop near the optic nerves and chiasm.
Backlund reported on the use of SRS in the multi modality approach to this tumor (24) . This paper reported on 42 adult and pediatric patients (age range, 5 to 63 years) admitted to Karolinska Hospital for a previously untreated craniopharyngioma. Follow-up ranged from 10-23 years. For 25 patients, the treatment consisted of intracavitary yttrium-90 for the cystic portion of the tumor and/or SRS for the solid tumor component. Most of the patients responded to the therapy..
Chung reported on their experience of 31 consecutive patients who underwent Gamma Knife radiosurgery and stereotactic procedures (25) . Nine of the patients were under 16 years old. The dose to the tumor margin ranged from 9.5 to 16 Gy. The visual pathways received less than 8 Gy. Tumor control was achieved in 87% of the patients with a 32.7% complete response rate. Only one patient experienced a mildly restricted visual field.
Another series from Mokry reported on 23 patients who had SRS as part of the overall treatment strategy (26) . Eleven of these patients were younger than 15 years. Ten patients underwent cyst drainage and aspiration for instillation of bleomycin. Using a mean dose of 10.8 Gy, volume reduction occurred in 74% of the patients. In most cases, the dose to the optic pathways was restricted to 9 Gy. Recurrence occurred in 5 patients with large multicystic residual or recurrent tumors.
For selected patients, SRS is an effective option that results in radiographic responses. With the emergence of stereotac- Volume 2, Number2, April 2003 tic radiotherapy, future studies are needed to evaluate the advantages and disadvantages of SRS compared to SRT.
Pineal Tumors
Pineal tumors account for less than 2% of all primary CNS tumors. The most common tumors that occur in this area include germ cell and pineal parenchymal tumors. Depending on the histology and extent of disease, radiation options can range from localized fields to CSl. Stereotactic radiosurgery has been used for recurrent and newly diagnosed patients with good results (27) (28) (29) .
Pituitary Adenomas
Pituitary adenomas are uncommon in children. Treatment options include surgery, medical therapy, external beam radiation therapy, and SRS. For secretory tumors, the use of SRS decreases hormone levels faster than fractionated radiation treatments. Thoren reported complete endocrine remission with normalization of urinary cortisol in 7 of 8 children with Cushing's disease (30) . Hypopituitarism was a common complication in these patients. Another series from Kobayashi of 25 patients (2 children) also reported excellent results (31) . Both children (ages 10 and 15 years) had a complete response on MRI and normalization of ACTH and cortisol levels using a prescription dose of 40 to 50 Gy.
Acoustic Neuromas
Acoustic neuromas are benign, slow growing tumors that can be managed by a number of treatment approaches. Stereotactic radiosurgery is an effective treatment option. In children, these tumors are seen in association with neurofibromatosis type 2. As a result, hearing preservation is important. Based on the adult literature, hearing can be preserved using MRI-based planning and low radiation doses (32) .
Kondziolka reported on 5 children with neurofibromatosis treated by SRS (33) . Follow-up imaging at a mean of 23 months showed that the tumors had decreased in size or stabilized in 5 patients. One patient required resection for recurrence. Since 1992, MRI-based planning and low SRS doses (12 to 14 Gy) have been used in 9 patients, 6 of whom retained useful hearing (34) .
Meningiomas
Meningiomas account for 1% to 3% of pediatric intracranial tumors. For patients with multiple menigiomas or isolated tumors, the diagnosis of neurofibromatosis type 2 needs to be considered. The treatment of choice is complete surgical resection. For those patients with malignant subtypes, radiation therapy can be considered. Based on the extensive adult literature, SRS can be considered for those patients who require radiation. Like other pediatric tumors, the literature for SRS is very limited. Eder reported on 2 skull base meningiomas that markedly reduced in size after Gamma Knife radiosurgery (35) .
Neurocytomas
Neurocytomas are uncommon tumors that arise from the septum pellucidum or the walls of the lateral ventricle. They typically occur in the second and third decade of life and can have a variable natural history. Primary treatment is complete surgical removal. For incompletely resected tumors, postoperative radiotherapy appears to improve local control (36, 37) .
Tyler-Kabara et al. reported on 4 patients who underwent SRS after initial biopsy or resection (38) . All patients had significant reduction of tumor size using tumor margin doses of 14 to 20 Gy. A 16-year-old female with a tumor volume of 7.9 cc had complete response whereas a 10-year-old male experienced a marked reduction in his tumor volume of 1.3 cc. None of the 4 patients had neurologic deficit.
Logistical Issues
The use of stereotactic radiosurgery poses some unique technical problems that limit its use in this population. Most single fraction systems rely on securing a stereotactic frame to the patient's head, typically using screw pins that engage the outer skull under pressure. In children under two years of age, this method of fixation is often not feasible due to the lack of fusion of the bony plates of the skull and the thinness of these bones. Attempts to create plaster casts and other methods of fixation have been tried with mixed results and should probably be reserved for use with fractionated radiosurgery.
Children, including some adolescents, also may not psychologically tolerate the process of frame application and treatment as an awake or sedated procedure. As a result, general anesthesia is often required. The use of general anesthesia for patients undergoing SRS poses additional challenges for the anesthesiologist. In particular, it requires prolonged anesthesia, the placement of a stereotactic head frame, patient transport to various areas within the hospital for imaging, and observation of the patient from outside the treatment room (39) . It is our practice to observe children overnight if they have been under extended general anesthesia.
Cleveland Clinic Experience
The Cleveland Clinic started its stereotactic radiosurgery program in 1989. From August 1989 through December 2002, more than 1250 patients have been treated with SRS. We initially started the program using a modified linear Summary accelerator. Since January 1997, we have used the Gamma Knife as our radiosurgery platform. 5 cases were treated with a linear accelerator-based system and 13 were treated with the Gamma knife. *One patient was treated on two different occasions. ** One patient was treated on two different occasions. tumors is unknown. Nevertheless, SRS has shown 10 be a valuable option for selected patients. The toxicities, costs, results of treatment, and quality of life indicators need to be carefully assessed for patients undergoing SRS. Future research is needed to determine the potential benefits and disadvantages of SRS compared with stereotactic radiotherapy.
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Diagnosis
Stereotactic radiosurgery represents an important treatment modality for selected pediatric brain tumors. Unfortunately, the number of papers regarding its use is sparse. In addition, there are no multi-institutional or cooperative group trials currently evaluating the use of SRS in children with brain tumors. As a result, the optimal use of SRS in pediatric brain At our institution, the patient is initially sedated using inhalation induction at the Gamma Knife suite. An intravenous line is started with an infusion of muscle relaxants and a narcotic. Once the patient is sedated, the anesthesiologist intubates the patient with an endotracheal tube. The neurosurgeon then places the stereotactic head frame. Anesthesia is sustained by using propofol (Diprivan). With this particular anesthetic, the depth of anesthesia can be kept stable and is easily reversible.
Sixteen pediatric patients have been treated at our center (about I% of all our SRS patients). Four patients were treated with the linear accelerated-based system, and 12 patients were treated with the Gamma Knife. The median age was 12 years old (range, 3 to 17 years). General anesthesia was used for 13 of 16 patients. Overall, the procedure has been well tolerated and has produced favorable results. Table I lists the various diagnoses that have been treated with SRS.
Before starting treatment, the cameras are arranged so the patient and various monitors can be visualized. Toward the end of the treatment, the anesthesiologist decreases the amount of propofol used. Once the treatment has been completed, the propofol is stopped, the muscle relaxant is reversed. and the frame is removed. When the patient is breathing on his or her own. the endotracheal tube is removed. He or she is then transferred to the PACU for observation. Pediatric patients are usually discharged home the following day.
